INTRODUCTION

BRILINTA 90MG contains ticagrelor which belongs to the group of medicines called antiplatelet agents. It is used to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. It also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS. Ticagrelor stops clumping of blood cells called platelets, which is responsible for clot formation in diseased blood vessels of heart and brain and thus reduces the chances of a blood clot formation. It can be taken with or without food.

The most common side effect of taking this medicine are bleeding and bruising. Avoid concomitant use of ticagrelor and other oral anticoagulants like heparin or warfarin, as it may increase the risk of side effects. Do not take this medicine if you are suffering from any bleeding disorders or liver problems. This medicine is not recommended for use in pregnant or breastfeeding women and in children aged below 18 years.

USES OF BRILINTA 90MG

• Prevents cardiovascular death, myocardial infarction and stroke in patients with ACS or myocardial infarction

HOW BRILINTA 90MG WORKS

Ticagrelor is a potent P2Y12 receptor antagonist. In diseased blood vessels, platelets can form thrombus (blood clot) by binding to the arterial surface. Activated platelets produces ADP3 which binds to P2Y12 receptor and propagates thrombus formation. Ticagrelor reversibly binds to P2Y12 receptor instead of ADP3 and prevents the signal transduction and platelet activation, that can lead to blood clot formation.

DIRECTIONS FOR USE

Take this medicine as directed by your physician. It can be taken with or without food. Your doctor will decide the correct dose for you depending upon your condition. Swallow the medicine with a glass of water. If you have trouble in swallowing the medicine, you can crush it and mix with half a glass of water. Stir and drink immediately. Continue to take this medicine, as long as your doctor tells you to do so, to obtain better results.

SIDE EFFECTS OF BRILINTA 90MG

HOW TO MANAGE SIDE EFFECTS

Feeling sick (nausea):

Try taking this medicine with, or just after meal. Stick to simple meals. Do not eat rich or spicy food.

Constipation: 

Eat fibre rich foods like fresh fruit, vegetables and cereals. Drink plenty of water. Exercise more regularly.

Diarrhea:

Drink lots of fluids, such as water or juice, to avoid dehydration. Do not take any medicines without speaking to a doctor.

Headache:  

Apply hot or cold-water bag on your head. Take rest in a quiet and dark room. Drink tea or coffee.

WARNING & PRECAUTIONS

INTERACTIONS

Talk to your doctor, if you are taking,

• other oral anticoagulants (e.g. heparin, warfarin)
• medicines used to treat high cholesterol levels (e.g. simvastatin or lovastatin)
• medicines used to treat epilepsy (e.g. phenytoin, carbamazepine and phenobarbital)
• medicines used to treat depression (e.g. paroxetine, nefazodone, sertraline and citalopram)
• medicines used to treat heart problems like heart failure (e.g. digoxin), abnormal heart rate (e.g. quinidine and diltiazem) or high blood pressure (e.g. propranolol, verapamil, captopril)
• non-steroidal anti-inflammatory drugs (used to treat pain) e.g. ibuprofen and naproxen
• rifampicin (used to treat tuberculosis)
• cyclosporine (used to avoid graft rejection)
• morphine and other opioids (used to treat severe pain)
• ketoconazole (used to treat fungal infections)
• clarithromycin (used to treat bacterial infections)
• ritonavir and atazanavir (used to treat HIV infection)
• cisapride (used to treat heartburn)
• ergot alkaloids (used to treat migraine headaches)

SYNOPSIS

MORE INFORMATION

Store at room temperature and keep out of reach of children.

REFERENCES

1. Keith A.A. Fox, Harvey D. White, Bernard J. Gersh and Lionel H. Opie. Antithrombotic Agents: Platelet Inhibitors, Acute Anticoagulants, Fibrinolytics and Chronic Anticoagulants. Drugs for the heart. 8th Edition. 2013. Page - 351-352.

2. Gerald G. Briggs, Roger K. Freeman. T. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation, Tenth Edition. 2015. Page – 3799-3800.

3. Jolanta M Siller-Matula, Bernd Jilma. Ticagrelor: from discovery to Phase III clinical trial. NIH National Library of Medicine, National center of Biotechnology information. November 2010. [Accessed 27th October 2020] https://pubmed.ncbi.nlm.nih.gov/21142630/

4. Dominick J. Angiolillo , George D. Dangas. Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention – TWILIGHT. American college of cardiology. March 2020. [Accessed 27th October 2020] https://www.acc.org/latest-in-cardiology/clinical-trials/2019/09/24/23/30/twilight

5. AstraZeneca AB; Electronic Medicines Compendium (EMC) [Revised on September 2019] Accessed 27th October 2020] https://www.medicines.org.uk/emc/files/pil.5767.pdf

6. AstraZeneca AB; Electronic Medicines Compendium (EMC) [Revised on September 2019] Accessed 27th October 2020] https://www.medicines.org.uk/emc/files/pil.7606.pdf

USEFUL DIAGNOSTIC TESTS

• Electrocardiogram (ECG)